Blood biomarker study shows benefits of combining p-tau181 and p-tau231

A study of plasma phosphorylated tau (p-tau) biomarkers has shown that p-tau181 and p-tau231 provide complementary rather than overlapping information.

Using the combination of p-tau epitopes can provide additional information to better characterize Alzheimer’s disease (AD) pathology in both research and clinical settings, the researchers suggested.

At AAIC 2021, Pamela Ferreira from the Universidade Federal do Rio Grande do Sul (UFRGS), in Porto Alegre, Brazil, reported findings from a study of 277 subjects: 38 with Alzheimer’s disease (AD), 54 with mild cognitive impairment MCI), 30 cognitively unimpaired younger adults, and 155 cognitively unimpaired elderly people. The individuals with AD or MCI were classified as cognitively impaired.